Last updated: March 8, 2026
What is NDC 71921-0309?
NDC 71921-0309 refers to a specific drug product listed in the National Drug Code database. It is a biosimilar ("SB5," or a similar formulation) that mimics the reference biologic, often used for indications such as rheumatoid arthritis, psoriatic arthritis, and certain cancers.
The product was approved by the FDA in 2019, targeting the biosimilar market. It competes directly with the originator biologic, Enbrel (etanercept).
Market Overview
Industry Context
The biosimilar market in the U.S. is expanding as biologic patents expire. Biosimilars typically cost 15-30% less than brand-name biologics. This specific biosimilar, likely a form of etanercept, targets multiple high-prevalence conditions with an estimated total addressable market (TAM) in the U.S. approximately valued at $4-5 billion annually.
Favorable reimbursement policies and increasing adoption by healthcare providers drive growth. However, market penetration faces barriers such as prescriber familiarity, patient acceptance, and formulary positioning.
Current Market Position
As a 2019 FDA-approved biosimilar, NDC 71921-0309 has secured initial market entry. Its market share growth depends on provider confidence and insurance coverage policies. Data from IQVIA indicate biosimilar penetration in the anti-TNF class reached 20% within two years post-launch, with projections of reaching 50% by 2025.
Competition Landscape
| Product Name |
Type |
Approval Year |
Market Share (2022) |
Pricing Discount from Reference |
Notes |
| Enbrel (etanercept) |
Original biologic |
1998 |
80% |
N/A |
Dominant market incumbent |
| SB5 (NDC 71921-0309) |
Biosimilar |
2019 |
Approximately 3-5% |
20-25% cheaper than Enbrel |
Growing but limited share initially |
Usage and Adoption Trends
Physician adoption typically lags regulatory approval by 12-24 months. In the biosimilar anti-TNF space, prescribers tend to favor the reference biologic initially. Education and formulary introductions gradually increase biosimilar use.
Sales data suggest 2022 U.S. biosimilar anti-TNF sales reached around $900 million. The growth rate for biosimilar etanercept approximates 30-35% annually in the recent calendar years.
Price Projections
Current Pricing Structure
Estimated wholesale acquisition cost (WAC):
- Reference biologic (Enbrel): ~$2,800 per 50 mg pen/week
- Biosimilar (NDC 71921-0309): approximately 20-25% discount (~$2,100–$2,240 per 50 mg pen/week)
Short-Term (2023-2025) Price Dynamics
| Year |
Expected WAC Price (per 50 mg pen/week) |
Key Factors |
| 2023 |
$2,100 - $2,240 |
Market penetration expansion, payer negotiations |
| 2024 |
$2,050 - $2,200 |
Increased uptake, competitive pricing by manufacturers |
| 2025 |
$2,000 - $2,150 |
Greater biosimilar acceptance, potential rebate enhancements |
Long-Term (2026-2030) Price Trends
Pricing may decrease further as competition intensifies:
- Price reduction rate of 3-5% annually expected
- Price could stabilize at around $1,800–$2,000 per 50 mg pen/week in the late 2020s
Impact of Policy and Market Forces
- Legislative efforts promoting biosimilar substitution could accelerate price declines.
- Patent litigations and exclusivities may temporarily limit biosimilar market penetration.
- Payer formulary preferences critically influence net price and market share.
Revenue Projections
Assuming steady market adoption and discounts, annual U.S. sales could reach:
| Year |
Estimated Market Share |
Projected Revenue (USD) |
Remarks |
| 2023 |
5-8% |
$200-$380 million |
Entry phase, initial uptake |
| 2025 |
20-30% |
$800-$1,200 million |
Adoption accelerates |
| 2030 |
50%+ |
$2.4 billion+ |
Dominant biosimilar in class |
Strategic Considerations
- Increased biosimilar prescribing depends on formulary moves and provider education.
- Pricing pressure remains high; companies focus on volume growth.
- Partnerships with payers can improve reimbursement and market share.
Key Takeaways
- NDC 71921-0309 is part of the competitive biosimilar anti-TNF market targeting high-value indications.
- Market share remains limited but is poised for significant growth, driven by decreasing prices and increased acceptance.
- Prices are projected to decline gradually over the next five years, reaching approximately $1,800 per 50 mg pen/week.
- Market dynamics depend heavily on payer policies, prescriber preferences, and legal landscape.
- Revenue projections suggest that by 2030, biosimilar sales could surpass $2 billion annually for this product class.
FAQs
-
How will biosimilar pricing evolve over the next decade?
Prices are expected to decline gradually, with discounts potentially reaching 30-35% below reference biologic prices by 2030.
-
What factors influence biosimilar market share growth?
Reimbursement policies, formulary coverage, physician acceptance, and patient education are primary drivers.
-
Is the price of NDC 71921-0309 competitive?
Yes, initially priced 20-25% below the reference biologic, with room for further reduction as market penetration increases.
-
What regulatory hurdles could impact market growth?
Patent litigation, exclusivity periods, and evolving biosimilar substitution laws can delay or limit market expansion.
-
When is significant biosimilar market share expected?
Expected to reach over 20% by 2025, with dominance possible by 2030 depending on market and policy developments.
References
[1] IQVIA. (2022). Biologic and biosimilar sales data.
[2] U.S. Food and Drug Administration. (2019). Approval announcement of SB5 biosimilar.
[3] Center for Biosimilars. (2022). Market trends and projections.
[4] GoodRx. (2023). Biosimilar pricing estimates.
[5] Patheon. (2022). Legislative updates impacting biosimilar adoption.
